FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990622503> ?p ?o ?g. }

• W1990622503 endingPage "75" @default.
• W1990622503 startingPage "70" @default.
• W1990622503 abstract "Purpose: Treatment options are limited for advanced pancreatic cancer progressive after gemcitabine therapy. The vascular endothelial growth factor pathway is biologically important in pancreatic cancer, and docetaxel has modest antitumor activity. We evaluated the role of the anti-vascular endothelial growth factor antibody bevacizumab as second-line treatment for patients with metastatic pancreatic cancer. Design: Patients with metastatic adenocarcinoma of the pancreas who had progressive disease on a gemcitabine-containing regimen were randomized to receive bevacizumab alone or bevacizumab in combination with docetaxel. Results: Thirty-two patients were enrolled; 16 to bevacizumab alone (Arm A) and 16 to bevacizumab plus docetaxel (Arm B). Toxicities were greater in Arm B with the most common grade 3/4 nonhematologic toxicities including fatigue, diarrhea, dehydration, and anorexia. No confirmed objective responses were observed. At 4 months, 2 of the 16 patients in Arm A and 3 of the 16 patients in Arm B were free from progression. The study was stopped according to the early stopping rule for futility. Median progression-free survival and overall survival were 43 days and 165 days in Arm A and 48 days and 125 days in Arm B. Elevated d-dimer levels and thrombin-antithrombin complexes were associated with decreased survival and increased toxicity. Conclusion: Bevacizumab with or without docetaxel does not have antitumor activity in gemcitabine-refractory metastatic pancreatic cancer. Baseline and on-treatment d-dimer and thrombin-antithrombin complex levels are associated with increased toxicity and decreased survival." @default.
• W1990622503 created "2016-06-24" @default.
• W1990622503 creator A5018244695 @default.
• W1990622503 creator A5021223600 @default.
• W1990622503 creator A5023000705 @default.
• W1990622503 creator A5045107557 @default.
• W1990622503 creator A5049901305 @default.
• W1990622503 creator A5053128814 @default.
• W1990622503 creator A5059061992 @default.
• W1990622503 creator A5065431287 @default.
• W1990622503 creator A5087332592 @default.
• W1990622503 creator A5089998052 @default.
• W1990622503 creator A5090472587 @default.
• W1990622503 date "2011-02-01" @default.
• W1990622503 modified "2023-09-25" @default.
• W1990622503 title "Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma" @default.
• W1990622503 cites W152343487 @default.
• W1990622503 cites W1539571840 @default.
• W1990622503 cites W1931508686 @default.
• W1990622503 cites W1964589941 @default.
• W1990622503 cites W1971811939 @default.
• W1990622503 cites W1974906718 @default.
• W1990622503 cites W1975440632 @default.
• W1990622503 cites W1989664813 @default.
• W1990622503 cites W1990161374 @default.
• W1990622503 cites W1991792727 @default.
• W1990622503 cites W1994861753 @default.
• W1990622503 cites W2000292756 @default.
• W1990622503 cites W2009337734 @default.
• W1990622503 cites W2013564192 @default.
• W1990622503 cites W2021020268 @default.
• W1990622503 cites W2026663786 @default.
• W1990622503 cites W2042098847 @default.
• W1990622503 cites W2052492883 @default.
• W1990622503 cites W2058405988 @default.
• W1990622503 cites W2067141748 @default.
• W1990622503 cites W2082243630 @default.
• W1990622503 cites W2085355966 @default.
• W1990622503 cites W2087884039 @default.
• W1990622503 cites W2094068309 @default.
• W1990622503 cites W2096134439 @default.
• W1990622503 cites W2098282622 @default.
• W1990622503 cites W2099274861 @default.
• W1990622503 cites W2100945863 @default.
• W1990622503 cites W2109134893 @default.
• W1990622503 cites W2124863710 @default.
• W1990622503 cites W2125447919 @default.
• W1990622503 cites W2126275851 @default.
• W1990622503 cites W2130637301 @default.
• W1990622503 cites W2136438977 @default.
• W1990622503 cites W2139248078 @default.
• W1990622503 cites W2145835533 @default.
• W1990622503 cites W2157769714 @default.
• W1990622503 cites W2158134441 @default.
• W1990622503 cites W2230554281 @default.
• W1990622503 cites W2339361819 @default.
• W1990622503 cites W82876830 @default.
• W1990622503 doi "https://doi.org/10.1097/coc.0b013e3181d2734a" @default.
• W1990622503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3030655" @default.
• W1990622503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20458210" @default.
• W1990622503 hasPublicationYear "2011" @default.
• W1990622503 type Work @default.
• W1990622503 sameAs 1990622503 @default.
• W1990622503 citedByCount "32" @default.
• W1990622503 countsByYear W19906225032012 @default.
• W1990622503 countsByYear W19906225032013 @default.
• W1990622503 countsByYear W19906225032014 @default.
• W1990622503 countsByYear W19906225032015 @default.
• W1990622503 countsByYear W19906225032016 @default.
• W1990622503 countsByYear W19906225032017 @default.
• W1990622503 countsByYear W19906225032018 @default.
• W1990622503 countsByYear W19906225032019 @default.
• W1990622503 countsByYear W19906225032021 @default.
• W1990622503 countsByYear W19906225032023 @default.
• W1990622503 crossrefType "journal-article" @default.
• W1990622503 hasAuthorship W1990622503A5018244695 @default.
• W1990622503 hasAuthorship W1990622503A5021223600 @default.
• W1990622503 hasAuthorship W1990622503A5023000705 @default.
• W1990622503 hasAuthorship W1990622503A5045107557 @default.
• W1990622503 hasAuthorship W1990622503A5049901305 @default.
• W1990622503 hasAuthorship W1990622503A5053128814 @default.
• W1990622503 hasAuthorship W1990622503A5059061992 @default.
• W1990622503 hasAuthorship W1990622503A5065431287 @default.
• W1990622503 hasAuthorship W1990622503A5087332592 @default.
• W1990622503 hasAuthorship W1990622503A5089998052 @default.
• W1990622503 hasAuthorship W1990622503A5090472587 @default.
• W1990622503 hasBestOaLocation W19906225032 @default.
• W1990622503 hasConcept C121608353 @default.
• W1990622503 hasConcept C126322002 @default.
• W1990622503 hasConcept C141071460 @default.
• W1990622503 hasConcept C143998085 @default.
• W1990622503 hasConcept C2776694085 @default.
• W1990622503 hasConcept C2777802072 @default.
• W1990622503 hasConcept C2780210213 @default.
• W1990622503 hasConcept C2780258809 @default.
• W1990622503 hasConcept C2781190966 @default.
• W1990622503 hasConcept C71924100 @default.
• W1990622503 hasConcept C90924648 @default.

• next